Vyondys 53 access guide: country options for cross-border named-patient access
Editorial and clinical review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.
About Vyondys 53
Vyondys 53 (golodirsen) is a antisense oligonucleotide (phosphorodiamidate morpholino, PMO) exon-skipping therapy approved by the US Food and Drug Administration for Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping. The current FDA label is available at accessdata.fda.gov. Vyondys 53 is marketed by Sarepta Therapeutics. Reserve Meds coordinates US-sourced cross-border access to Vyondys 53 under the named-patient and personal-import framework that governs reference-authority-approved medicines in the patient jurisdiction, with chain-of-custody documentation under the US Drug Supply Chain Security Act (DSCSA). The country-specific access guides listed below set out the regulatory pathway, the tertiary referral context, the documentation bundle the treating physician of record submits to the regulator, and the how to request a written quote for Vyondys 53 in each jurisdiction Reserve Meds has authored.
Vyondys 53 country-specific access guides
Reserve Meds has published 15 country-specific access guides for Vyondys 53. Each guide covers the regulatory pathway, the tertiary referral context, the documentation package, how quotes work, and the operational sequence Reserve Meds coordinates for that jurisdiction.
Bahrain
Read the Bahrain access guide for Vyondys 53.
Read the guideEgypt
Read the Egypt access guide for Vyondys 53.
Read the guideIndia
Read the India access guide for Vyondys 53.
Read the guideIraq
Read the Iraq access guide for Vyondys 53.
Read the guideJordan
Read the Jordan access guide for Vyondys 53.
Read the guideKuwait
Read the Kuwait access guide for Vyondys 53.
Read the guideLebanon
Read the Lebanon access guide for Vyondys 53.
Read the guideOman
Read the Oman access guide for Vyondys 53.
Read the guidePakistan
Read the Pakistan access guide for Vyondys 53.
Read the guideQatar
Read the Qatar access guide for Vyondys 53.
Read the guideSaudi Arabia
Read the Saudi Arabia access guide for Vyondys 53.
Read the guideSri Lanka
Read the Sri Lanka access guide for Vyondys 53.
Read the guideUAE
Read the UAE access guide for Vyondys 53.
Read the guideArabic-language guides are available for: Bahrain, India, Kuwait, Qatar, Saudi Arabia, UAE. Switch languages via the page footer or the URL prefix /ar/.
Other countries
Reserve Meds has authored country-specific access guides for Vyondys 53 in the 15 jurisdictions listed above. If your country is not on this list, a lawful pathway may still be available. The Reserve Meds case team will scope your case under the same named-patient or personal-import framework that governs the published guides.
Request a Vyondys 53 access scope for your country
Related Reserve Meds resources
Illustrative example cases (composites, not real patients). This content is for general information and does not constitute medical advice. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating physician.
Editorial review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.
Frequently asked questions
How can I get Vyondys 53 if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Vyondys 53 for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Vyondys 53 through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Vyondys 53. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Vyondys 53 through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Vyondys 53 to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Vyondys 53 to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Vyondys 53 cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Vyondys 53?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.